Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
17.13B
Market cap17.13B
Price-Earnings ratio
19.48
Price-Earnings ratio19.48
Dividend yield
Dividend yield
Average volume
569.04K
Average volume569.04K
High today
$272.37
High today$272.37
Low today
$260.75
Low today$260.75
Open price
$268.72
Open price$268.72
Volume
473.46K
Volume473.46K
52 Week high
$282.15
52 Week high$282.15
52 Week low
$186.05
52 Week low$186.05

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $260.81, giving the company a market capitalization of 17.13B. It carries a P/E multiple of 19.48.

On 2026-09-10, Ascendis Pharma A/S(ASND) stock moved within a range of $260.75 to $272.37. With shares now at $260.81, the stock is trading +0.0% above its intraday low and -4.2% below the session's peak.

Trading volume for Ascendis Pharma A/S(ASND) stock has reached 473.46K, versus its average volume of 569.04K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

ASND News

TipRanks 5h
Top Ascendis Pharma Executive Makes Bold Move With Major Stock Sale

New insider activity at Ascendis Pharma ( (ASND) ) has taken place on September 9, 2026. Ascendis Pharma’s Senior Vice President & Principal Accounting Officer,...

TipRanks 9h
Ascendis Pharma Posts Positive 52-Week Infant Achondroplasia Data for TransCon CNP

The latest announcement is out from Ascendis Pharma ( (ASND) ). On Sept. 9, 2026, Ascendis Pharma reported Week 52 data from a seven-infant open-label sentinel...

TipRanks 11h
Ascendis Pharma announces data from reACHin Trial

Ascendis Pharma (ASND) announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial showing that treatment with once-weekly TransCon...

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

Simply Wall St 5d
Ascendis Pharma Could Be 14% Undervalued Following Yorvipath Reimbursement Progress

Ascendis Pharma (NasdaqGS:ASND) is back in focus after Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath, its parathyroid hormone...

Ascendis Pharma Could Be 14% Undervalued Following Yorvipath Reimbursement Progress

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.